Processing...
Clinical Trials for Sarcoma
Search
Search
There are 166 active trials for advanced/metastatic sarcoma.
Click on a trial to see more information.
166 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Single-arm maintenance trial for children and young adults (<40) with relapsed/refractory Ewing sarcoma or osteosarcoma who are now NED after completing relapse therapy, ECOG 0–2, with adequate organ function. Participants receive oral DFMO (eflornithine), an irreversible ornithine decarboxylase inhibitor that depletes polyamines, given twice daily in 28‑day cycles for up to 2 years to delay recurrence.
ClinicalTrials.gov ID: NCT06892678
TrialFetch AI summary: Adults with metastatic/recurrent liposarcoma (WD/DD with MDM2 amplification or myxoid subtype) or CIC-rearranged sarcoma receive oral BTX-A51 three times weekly; BTX-A51 is an investigational multikinase inhibitor (targets CK1α and CDK7/CDK9) intended to stabilize p53 by suppressing MDM2 and downregulate oncogenic transcription (e.g., MYC, MCL1). Two fixed dose levels (21 mg or 30 mg) are explored with treatment until progression or unacceptable toxicity.
ClinicalTrials.gov ID: NCT06414434
TrialFetch AI summary: Adults with metastatic or unresectable soft tissue sarcoma—emphasis on leiomyosarcoma—after prior therapy (including limited prior anthracycline) receive oral peposertib (DNA-PK inhibitor targeting NHEJ repair) continuously with low-dose pegylated liposomal doxorubicin every 28 days. Includes dose escalation across selected STS subtypes and a leiomyosarcoma expansion; requires biopsy-amenable disease, allows treated/stable CNS metastases, and excludes significant cardiac dysfunction and prior DNA-PK inhibitor exposure.
ClinicalTrials.gov ID: NCT05711615
TrialFetch AI summary: Adults with recurrent, measurable primary CNS gliomas harboring BRAF V600E mutations after prior BRAF/MEK inhibitor therapy, eligible for resection/biopsy with ventricular reservoir, receive plixorafenib (paradox-breaking BRAF inhibitor that disrupts RAF dimer signaling) plus cobicistat. The study includes serial CSF and plasma sampling to assess ctDNA dynamics alongside MRI response while patients continue oral therapy until progression.
ClinicalTrials.gov ID: NCT06610682
TrialFetch AI summary: Children and young adults with relapsed/refractory solid tumors—phase II focused on neuroblastoma and Ewing sarcoma—receive silmitasertib, an oral CK2 inhibitor (modulates PI3K/AKT and DNA damage response), combined with standard salvage chemotherapy backbones. Regimens include silmitasertib + irinotecan/temozolomide for neuroblastoma and silmitasertib + vincristine/irinotecan/temozolomide for Ewing sarcoma.
ClinicalTrials.gov ID: NCT06541262
TrialFetch AI summary: Children and young adults (2–30 years) with relapsed/refractory solid tumors (e.g., neuroblastoma, sarcomas, Wilms tumor) after standard therapy receive lymphodepleting fludarabine/cyclophosphamide followed by a single IV infusion of autologous B7-H3–directed CAR T cells (targets CD276). B7-H3 expression testing is required on tissue (positivity not mandatory); key exclusions include uncontrolled infection, active viral hepatitis/HIV, recent significant cardiac disease, untreated brain metastases, and need for systemic immunosuppression.
ClinicalTrials.gov ID: NCT06500819
TrialFetch AI summary: Enrolling pediatric (1 to <18 years) and young adult patients with relapsed/refractory B-ALL, DLBCL/Burkitt lymphoma, neuroblastoma, or Ewing sarcoma to receive single‑agent zilovertamab vedotin IV every 21 days in dose-escalation/expansion cohorts. Zilovertamab vedotin is a ROR1‑targeted antibody–drug conjugate delivering MMAE to tumor cells; primary aims are safety/PK and preliminary efficacy with disease‑specific response criteria.
ClinicalTrials.gov ID: NCT06395103
TrialFetch AI summary: Adults with HLA‑A*02:01–positive unresectable or metastatic cutaneous melanoma (post–PD‑1) or synovial sarcoma needing further therapy receive autologous PRAME‑targeted TCR‑T cells (ACTengine IMA203) after lymphodepletion plus low‑dose IL‑2, combined with a PRAME mRNA vaccine (mRNA‑4203) to boost PRAME‑specific T‑cell responses. Key exclusions include active brain metastases, significant autoimmune/cardiac disease, prior allogeneic transplant, active viral infections, and hypersensitivity to study agents.
ClinicalTrials.gov ID: NCT06946225
TrialFetch AI summary: For children, adolescents, and young adults (≤21 years) with relapsed/refractory B7-H3 (CD276)–positive sarcomas (including osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, and other soft-tissue sarcomas) who have at least one lesion amenable to hypofractionated radiation. Treatment is hypofractionated radiation priming to ≥1 tumor site with fludarabine/cyclophosphamide lymphodepletion followed by IV infusion of autologous B7-H3–directed CAR T cells (genetically engineered T cells targeting the tumor antigen B7-H3).
ClinicalTrials.gov ID: NCT07222735
TrialFetch AI summary: Adults (≥18) with metastatic or unresectable soft tissue sarcoma (RECIST-measurable, ECOG 0–1) who have progressed after 1–3 prior metastatic lines (ASPS allowed without prior refractoriness) and have had no prior PD-1/PD-L1/CTLA-4 therapy or zanzalintinib/cabozantinib. Treatment is oral zanzalintinib (XL092), a multikinase TKI targeting VEGFR2/MET/TAM (TYRO3/AXL/MER), combined with nivolumab (PD-1 inhibitor) plus ipilimumab (CTLA-4 inhibitor) induction, followed by maintenance nivolumab with ongoing daily zanzalintinib.
ClinicalTrials.gov ID: NCT06968988